Spectrum of Bone and Soft Tissue Tumors in A Tertiary Cancer Institute in Eastern India

Vol 4 | Issue 2 | July-Dec 2018 | Page 7-10 | Ashwini Natekar, Gaurav Gupta, Subhasis Basu.


Authors: Ashwini Natekar [1], Gaurav Gupta [1], Subhasis Basu [1].

[1] Dept of Pathology, Chittaranjan national cancer institute, Kolkata, India

Address of Correspondence
Dr. Ashwini Natekar,
Dept of Pathology, Chittaranjan national cancer institute, Kolkata, India


Abstract

Introduction: Bone and soft tissue tumours are uncommon tumours that can affect any age group. Soft tissue tumors are said to be heterogeneous group of mesenchymal malignancies. Primary bone sarcomas are rare tumors, comprising approximately 0.2% of all cancers. Their true incidence is difficult to estimate because of their rarity.[1]The outcome of the disease depends on the age and time at diagnosis.
Material and Methods: A study was carried out in department of pathology in tertiary cancer institute in East India from December 2015 to September 2017. A total of 60 cases were included in the study. Clinical and radiological details of patients were noted along with gross specimen findings and microscopic examination of H &E stained slides. IHC was also carried out for confirmatory diagnosis.
Aims and Objecctives: 1- To study the histological spectrum of bone and soft tissue tumors in a tertiary cancer institute in Eastern India
2- To study gender distribution and site distributionof bone and soft tissue tumors
Results: Out of the total 60 cases studied 24 cases were of bone and cartilaginous tumours and 36 cases included were of soft tissue tumors. Benign tumors comprised of 08 cases (13.3%) and malignant tumors accounted to 52 cases (86.7%). Age of the patients ranged from 10 to 80 years. Male female ratio was 1.4:1.
Conclusion: Multimodal therapies of treatment is practiced for bone and soft tissue tumors. Early detection and treatment is essential for diagnosis of these malignant tumors. Molecular studies are most important in diagnosing, classifying and also prognosticating bone and soft tissue tumors.
Keywords: bone tumors, soft tissue tumors, histology.


References

1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al., editors. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 1975-2013. [Last accessed on 2016 Jun 01].
2. Jain P, Shrivastava A, Mallik R..Clinicomorphological Assessment of Soft Tissue Tumors. Sch J App Med Sci. 2014; 2(2D): p. 886-90.
3. Hassawi BA, Suliman AY, Hasan IS. Soft tissue tumours – Histopathological study of 93 cases. Ann Coll Med Mo sul.2-010; 36(1&2) : p. 92-8.
4. Weiss SW, Goldblum JR. General Considerations. In Enzinger & Weiss’s Soft Tissue Tumours, 4th edition.: Mosby Publication 2001; 20011-19.
5. Beg S, Vasenwala SM, Haider N, Ahmad SS,Maheshwari V, Khan MA. A comparison of cytological ad histopathological findings and role of immunostains in the diagnosis of soft tissue. J Cytol. 2012; 29(2): p. 125-130.
6. Lazim AF, Bedoor AK, Al-Irhayim. Soft tissue sarcomas in Mosul: a pathologic evaluation. Ann Coll Med Mosul. 20-08;34(2): p. 152-160.
7. Zhi-wei F, Jing C, Sheng T, Yong C, Rui-feng X. Analysis of soft tissue sarcomas in 1118 cases. Chinese Medical Journal.2009; 122(1): p. 51-53.
8. Batra P, Gupta DO, Batra R, Kothari R, Bokariya P.Pattern of Soft Tissue Tumours In A Rural Population Of Central India.Innovative Journal of Medical and Health Science. 2013 May – June; 3(3): p. 124-6.
9. Anant Ramaswamy, Bharat Rekhi,1 Sameer Bakhshi,2 Sachin Hingmire,3 and Manish Agarwal4Indian data on bone and soft tissue sarcomas: A summary of published study resultsSouth Asian Journal of Cancer.
10. Mark A. Applebaum, et al; Clinical features and outcomes in patients with extraskeletal Ewing sarcoma Cancer. 2011 Jul 1; 117(13): 3027–3032.
11. Askin FB, Rosai J, Sibley RK, Dehner LP, Mc Alister WH. Malignant small cell tumour of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer. 1979;43:2438–2451. doi: 10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9. [PubMed] [Cross Ref]
12. Sabati JM, Franquet T, Parellada JA, Monill JM, Oliva E. Malignant neuroectodermal tumour of the chest wall (Askin tumour): CT and MR findings in eight patients. Clinical Radiology. 1994;49:634–638. doi: 10.1016/S0009-9260(05)81882-3. [PubMed] [Cross Ref]
13. Winer-Muram HT, Kaufman WH, Gronemeyer SA, Gregory JS. Primitive neuroectodermal tumors of the chest wall (Askin tumors). CT and MR findings. Am J Res. 1985;145:517–520.
14. Dewan M, Malatani TS, Ansari MA. Lessons to be learned: A case study approach Malignant melanoma of soft tissue. J R Soc Health. 2005;125:42–6. [PubMed]
15. Crowson A, Magro C, Mihm M. Unusual histologic and clinical variants of melanoma: Implications for therapy. Curr Oncol Rep. 2007;9:403–10. [PubMed]
16 Lucas DR, Nascimento AG, Sim FH. Cell sarcoma of soft tissues: Mayo Clinic experience with 35 cases. Am J Surg Pathol. 1992;16:1197–204. [PubMed]
17. Enzinger FM. Clear cell sarcoma of tendons and aponeuroses: An analysis of 21 cases. Cancer. 1965;18:1163–76. [PubMed]
18. AF Mavrogenis,1 G Bianchi,2 NA Stavropoulos,1 PJ Papagelopoulos,1 and P Ruggieri2 Clinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft parts Hippokratia. 2013 Oct-Dec; 17(4): 298–302.
19. Meis Kindblom JM. Clear cell sarcoma of tendons and aponeuroses: A historical perspective and tribute to the man behind the entity. Adv Anat Pathol. 2006;13:286–92. [PubMed]
20. O. Hocar,1 A. Le Cesne,2 S. Berissi,1 P. Terrier,2 S. Bonvalot,2 D. Vanel,3 A. Auperin,4 C. Le Pechoux,2 B. Bui,5 J. M. Coindre,5 and C. Robert1Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases:Dermatology Research and Practice


How to Cite this article: Ashwini Natekar A, Gupta G, Basu S. Spectrum of Bone and Soft Tissue Tumors in A Tertiary Cancer Institute in Eastern India. Journal of Bone and Soft Tissue Tumors July – Dec 2018;4(2): 7-10.


                  (Abstract    Full Text HTML)   (Download PDF)


Guest Editorial – Asia Pacific Musculoskeletal Tumor Society Conference 2018

Vol 4 | Issue 2 | July-Dec 2018 | page: 2-3 | Ajay Puri.


Author: Ajay Puri [1].

[1] Orthopedic Oncology Services, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai.

Address of Correspondence
Dr. Ajay Puri,
Department of Orthopaedic Oncology, Room No: 26, Tata Memorial Hospital, Borges Road, Parel, Mumbai – 400 012. India.
Email: docpuri@gmail.com


Asia Pacific Musculoskeletal Tumor Society Conference 2018

For advances in musculo skeletal oncology to occur we need a host of clinical specialties along with nursing, rehabilitation and support staff interacting on a continuous basis. Sarcomas are rare and each individual and institution can only benefit from having access to pooled information and experience. For sarcoma care to evolve, ideas to surface and multi institute or multi-disciplinary collaborations to develop in the fields of basic research, patient care, biomaterials and prosthesis, there is a need for a common platform where all of us involved in the treatment of sarcomas can interact. Our socio economic milieu in the Asia Pacific region is unique. We have a spectrum ranging from resource rich societies with extensive state supported health care to resource constrained nations where patients have inconsistent access to health care and funding for health care is limited. Solutions and protocols applicable to the Western world need not necessarily be the most suitable in our scenario. Our large numbers coupled by the sheer native ingenuity necessary to offer quality health care in a resource challenged population can help us develop solutions that can be adapted everywhere.

The Asia Pacific Musculoskeletal Tumor Society (APMSTS) was conceptualized during discussions at the 7th International Symposium of Limb Salvage Surgeons (ISOLS) meeting in 1993 and its first meeting was held in 1995 in Japan under the stewardship of Professor Yoshio Ogihara. Mirroring a similar initiative, the Indian Musculo Skeletal Oncology Society (IMSOS) was established in 2013 to “promote scientific, evidence based, comprehensive multidisciplinary management of bone and soft tissue sarcomas and encourage basic and clinical research”. This year Jaipur, India plays host to the 12th APMSTS meeting in October. This is a joint meeting co-hosted with IMSOS. The theme of the conference is “Education – Collaboration – Innovation”. This epitomizes our desire to share and disseminate knowledge, the spirit of collaboration necessary to find answers to common problems and the need to derive innovative solutions best suited to our socio economic milieu.


The conference logo depicts the feathers of the peacock in the Indian national colours adorning a group of people with interlinked arms who represent the collaboration and camaraderie between individuals and countries that form the Asia Pacific Musculoskeletal Society. The logo represents the beauty and spirituality of India while signifying the desire to showcase skills from the Asia Pacific region. The peacock, the national bird of India symbolizes many of the qualities that we as “healers” must inculcate. In Hinduism, the peacock is associated with Saraswati the goddess of wisdom and learning. In Buddhism, the peacock is a symbol of purity and the ‘eyes’ in the peacock’s tail represent a symbol of watchfulness. The figure of the peacock is painted in various Islamic religious buildings while in Christianity the peacock was known as the symbol of resurrection and renewal. Just as the peacock elegantly unfolds its vibrant colours during its ritual dance, so too this conference is an occasion for us to demonstrate the best from all participating delegates.

We have more than 300 delegates from 28 countries participating in this meeting. Deviating from the accepted norm of didactic lectures the meeting focusses more on interactive sessions that will promote healthy discussion. There are case based panel discussions and sessions where senior musculoskeletal oncologists share their diverse experiences so that all attendees can benefit from the collective experience of others in order to enable them to make better decisions when managing similar cases. While providing adequate sessions for free papers there are two “show piece” orations. The IMSOS oration “Lessons learned from the European-American Osteosarcoma Study EURAMOS1” will be delivered by Prof. Stefan Bielack while the inaugural APMSTS “Prof. Yoshio Ogihara Oration” will be delivered by Dr. Suresh Nathan. The conference is preceded by multidisciplinary workshops that encompass all specialties involved in sarcoma care, offering delegates an opportunity to interact with faculty in smaller groups.

This unique joint meeting also offers the ideal platform to unveil a brief monograph “IMSOS guidelines for musculoskeletal sarcomas”, IMSOS’s endeavour to standardise the management of musculoskeletal sarcomas in India.

All our efforts are ultimately focussed on improving health care for our patients. A meeting such as this would be incomplete unless we involved them too. The IMSOS sarcoma support initiative will simultaneously conduct a parallel session that helps patients share their experience and presents an occasion where we can felicitate support personnel who selflessly give their time to enable us to optimise overall patient care.

We are sure the ambience and hospitality of Jaipur combined with an exciting and informative scientific programme will make this joint APMSTS – IMSOS conference a memorable and enriching event for all delegates.
It is our pleasure and privilege to welcome all attendees to Jaipur to partake of the experience that is “Incredible India”!

Prof. Ajay Puri
President – Indian Musculo Skeletal Oncology Society
President – Asia Pacific Musculoskeletal Tumor Society


How to Cite this article: Puri A. Asia Pacific Musculoskeletal Tumor Society 2018 Issue. Journal of Bone and Soft Tissue Tumors July-Dec 2018; 4(2):2-3.


(Abstract Full Text HTML) (Download PDF)


 

Denosumab Therapy Related Changes in Giant cell Tumor (Osteoclastoma) of Bone : A New Osteosarcoma Mimicker

Vol 4 | Issue 2 | July-Dec 2018 | Page 4-6 | Pradnya Manglekar, Sujit Joshi, Yogesh Panchwagh.


Authors: Pradnya Manglekar [1], Sujit Joshi [1], Yogesh Panchwagh [1].

[1] Dept. of Pathology Deenanath Mangeshkar Hospital and Research Centre, Pune
[2] Orthopaedic Oncology Clinic, Pune, India.

Address of Correspondence
Dr. Sujit Joshi,
Dept. of Pathology Deenanath Mangeshkar Hospital and Research Centre, Pune
Email: sujitjoshi30@gmail.com


Abstract

Objectives: Giant cell tumor (Osteoclastoma)of bone is locally aggressive osteolytic tumor. Denosumab–A monoclonal antibody against RANKL is recently being used to treat this tumor. We discuss histopathological changes occurring in giant cell tumor of bone after Denosumab treatment.
Method: A retrospective study of 12 cases from January 2014 to March 2018. All patients included were diagnosed as giant cell tumor (osteoclastoma) of bone on needle or open biopsy. Subsequently these patients received Denosumab therapy followed by surgical resection (extended curettage or wide excision). Histomorphological features after Denosumab therapy were evaluated in these specimens and compared with morphological features of prior biopsy samples.
Results: Needle or open biopsy samples studied prior to receiving Denosumab therapy showed typical morphological features of osteoclastoma i.e. presence of uniformly distributed osteoclastic cells and sheets of mononuclear stromal cells. No atypical mitoses or matrix production noted. Post Denosumab therapy resection specimens showed marked reduction in number of osteoclastic giant cells. There was predominance of mononuclear stromal cells along with abundant, irregular new bone (osteoid) formation with osteoid matrix deposition. Occasional mitotic activity was seen. Few foci of necrosis were noted.
Conclusion: Denosumab treatment causes significant giant cell depletion accompanied by abundant new bone formation separated by cellular stromal proliferation. These features bear very little resemblance to their pre-treatment counterparts and can mimic morphological features of osteosarcoma and other bone forming tumors. Hence, one should be aware of these changes so that a misdiagnosis of osteosarcoma can be avoided.
Keywords: Giant cell tumor (osteoclastoma), Denosumab, RANKL.


References

1. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease.9th edition. Saunders Elsevier: Philadelphia; 2015. Chapter 26, Bones, Joints and Soft tissue tumors; p1179 – 1226.
2. Rosai J. Rosai and Ackerman’s Surgical Pathology. 10thedition. Elsevier Mosby: St.Louis, Missouri; 2011. Chapter 24, Bone and joints; p2013-2104.
3. Branstetter DG, Nelson SD, Manivel JC, Blay JY et al. Denosumab induces Tumor Reduction and Bone formation in Patients with Giant-Cell Tumor of Bone. Clin Cancer Res; 18(16); 4415-24.2012 AACR.
4. Singh AS, Chawla NS, Chawla SP. Giant-cell tumor of bone: treatment options and role of denosumab. Biologics: Targets and Therapy 2015;9, 69-74.
5. Huang L, Teng XY, Cheng YY, Lee KM, Kumta SM. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts instromal tumour cells of giant cell tumour of bone. Bone 2004 Mar;34 (3):p393–401.
6. James IE, Dodds RA, Olivera DL, Nuttall ME, Gowen M. Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J Bone Miner Res 1996 Oct;11 (10):1453–60.
7. Wojcik J, Rosenberg AE, Bredella MA, et al. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J SurgPathol 2016 Jan; 40(1): 72-80.
8. Rekhi B, Verma V, Gulia A, et al. Clinicopathological features of a series of 27 cases of post-denosumab treated giant cell tumors ofbones: a single institutional experience at a tertiary cancer referralcentre, India. PatholOncol Res 2017 Jan; 23 (1): 157-64.
9. Chang-Che Wu, Pin-Pen Hsieh. Denosumab-Treated Giant Cell Tumor of the Bone Mimicking Low-Grade Central Osteosarcoma.Journal of Pathology and Translational Medicine 2018; 52: 133-135.


How to Cite this article: Manglekar P, Joshi S, Panchwagh Y. Denosumab Therapy Related Changes in Giant cell Tumor (Osteoclastoma) of Bone : A New Osteosarcoma Mimicker. Journal of Bone and Soft Tissue TumorsJuly-Dec 2018;4(2):4-6.


                  (Abstract    Full Text HTML)      (Download PDF)


JBST- Special APMSTS 2018 Issue

Vol 4 | Issue 2 | July-Dec 2018 | page:1 | Dr. Yogesh Panchwagh, Dr. Ashish Gulia,  Dr. Ashok Shyam.


Author: Yogesh Panchwagh [1], Ashish Gulia [2], Ashok Shyam [1,3].

[1] Orthopaedic Oncology Clinic, Pune, India.
[2] Orthopedic Oncology Services, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai.
[3] Indian Orthopaedic Research Group, Thane, India,
[4] Sancheti Institute for Orthopaedics &Rehabilitation, Pune, India

Address of Correspondence
Dr. Yogesh Panchwagh.
Orthopaedic Oncology Clinic, 101, Vasant plot 29, Bharat Kunj Society -2, Erandwana, Pune – 38, India.
Email: drpanchwagh@gmail.com


JBST- Special APMSTS 2018 Issue

It gives us immense pleasure in presenting the special IMSOS (Indian Musculoskeletal Oncology Society) issue of Journal of bone and soft tissue tumors on the occasion of the 12th Asia Pacific Musculoskeletal Tumor Society meeting, Jaipur, India. It’s only the second time, the first being in 2002, that APMSTS conference is being held in India. It is being co-hosted by the IMSOS, a relatively new body comprising of mostly the young but enthusiastic clinicians and paramedical staff involved in sarcoma care in India. Under the able presidentship of Dr Ajay Puri, a veteran in the field, the 12th APMSTS is all set to give the delegates a memorable experience. It’s but natural that Dr Ajay Puri, President – APMSTS 2018 and IMSOS has penned the guest editorial for this issue.

JBST (Journal of bone and soft tissue tumors) is proud to be associated with IMSOS as its official journal. All the members of IMSOS have contributed wholeheartedly to this issue echoing the theme of APMSTS 2018: “Education – Collaboration – Innovation”. The issue comprises of original articles on the data from institutes located across India on varied topics ranging from demographics of sarcoma in eastern India to osteosarcoma of facial bones from South India to recent topics like post denosumab changes in the histopathology of Giant cell tumors from western India. Even the case reports, which are rare clinical presentations of pathologies like osseous hydatid cyst, chordoma, clear cell chondrosarcoma, sacral inclusion cyst, hold a high educational value.

We also take this opportunity to invite all delegates to submit to Journal of Bone and Soft tissue tumors, which is one of the few journals that publish bone tumor research. We have a great editorial board and an online submission and review system. JBST has completed four years now and we are committed to make JBST the best resource for publishing bone tumor research in the world. This can be only achieved by co-operation and collaboration from all of you

We are happy to present this issue at the 12th APMSTS at Jaipur. Hope you will enjoy it as much as the vibrant, colourful and warm Indian hospitality.

Dr. Yogesh Panchwagh
Dr. Ashish Gulia
Dr. Ashok Shyam


How to Cite this article: Panchwagh Y, Gulia A, Shyam AK. JBST – Special APMSTS 2018 Issue. Journal of Bone and Soft Tissue Tumors July-Dec 2018; 4(2):1.

(Abstract Full Text HTML) (Download PDF)


 

Need for a dedicated Musculoskeletal Tumor Registry in India

Vol 3 | Issue 1 | May- Aug 2017 | page:1 | Dr. Yogesh Panchwagh & Dr. Ashok Shyam.


Author: Dr. Yogesh Panchwagh [1], Dr. Ashok Shyam [2,3].

[1]Orthopaedic Oncology Clinic, Pune, India.
[2] Indian Orthopaedic Research Group, Thane, India
[3] Sancheti Institute for Orthopaedics &Rehabilitation, Pune, India

Address of Correspondence
Dr. Yogesh Panchwagh.
Orthopaedic Oncology Clinic, 101, Vasanth plot 29, Bharat Kunj Society -2, Erandwana, Pune – 38, India.
Email: drpanchwagh@gmail.com


Need for a dedicated Musculoskeletal Tumor Registry in India

Registries are one of the most important resources for any disease. Around 200 cancer registries in the world that covering up mere 5% of worlds population was noted in 1999. However no parallel data exists currently but we are sure that number of cancer registries have increased over the period of time.India has an already existing National cancer registry program which was started in 1981 and is still running strong. However we belive that time has now come for a dedicated musculosketal registry in India. The technology has grown rapidly and now we have developed a simple mobile app which can collect most of the registry data in a very simple and user friendly way. We have been working on this concept sicne two years now and have taken inputs from many orthoonco surgeons. The mobile app is finally launched in the public domain and is available on google play store and app store. The app is named ‘MSK Registry’ and It can be downloaded for free by all interested in contributing cases. We would urge everyone to contribute and also write to us for any issues or queries

Regards.
Dr Yogesh Pachwagh
Dr Ashok Shyam

Yogesh Panchwagh & Ashok Shyam


How to Cite this article: Panchwagh Y, Shyam AK. Need for a dedicated Musculoskeletal Tumor
Registry in India. Journal of Bone and Soft Tissue Tumors Sep-Oct 2017; 3(1):1.

A B


(Abstract Full Text HTML) (Download PDF)


 

Plantar Fibromatosis Masquerading as Liposarcoma : a Case Report and Review of Literature

Volume 2 | Issue 2 | May-Aug 2016 | Page 25-29 | Nishit Bhatnagar, Purushotham Lingaiah, Sumit Arora, Anil Dhal.


Authors: Nishit Bhatnagar [1], Purushotham Lingaiah [1], Sumit Arora [1], Anil Dhal [1].

[1]Department of Orthopaedic Surgery, Maulana Azad Medical College & associated Lok Nayak Hospital, New Delhi-110002

Address of Correspondence
Dr. Nishit Bhatnagar
7 Godavari Apartments, Alaknanda, New Delhi – 19
E-mail id: nishitbhatnagar@yahoo.co.in


Abstract

Plantar fibromatosis and well differentiated liposarcoma can have a similar clinical presentation of a slow growing superficial well defined mass on the plantar aspect of foot. We present a patient of plantar fibromatosis mimicking a lipomatous tumour of the foot. Marginal resection of the remaining tumour was performed. At two years postoperatively, there has been no recurrence of the tumour.
Keywords: liposarcoma, foot, plantar fibromatosis


Introduction 

Plantar fibromatosis is a benign lesion involving the plantar aponeurosis. Ledderhose [1] in 1897 reported and described approximately 50 cases of contractures of the plantar fascia, leading to the entity being termed as Ledderhose’s disease. Its similarity to Dupuytrens’s disease of the hand has also led to the term “Dupuytren’s disease of the plantar fascia” [2]. It is commonly known to occur in the 3rd to 5th decade of life, has a male preponderance and is bilateral in 20 to 50% of cases [3,4,5]. It has an unknown etiology and is characterized by neoplastic proliferation of immature fibroblasts with spindle-shaped myofibroblasts within the plantar fascia [6]. They can be locally aggressive, demonstrate local recurrence but do not metastasize. Lipogenic tumours represent the most common soft tissue tumours [7]. Atypical and malignant lipomatous neoplasms are the most common variety of adult soft tissue sarcomas, accounting for nearly 20% of all sarcomas [8]. Lipomatous tumours are most frequently found in the extremities, retroperitoneum, groin and abdominal wall [9]. Lipomatous tumours can range from benign lipomas to highly malignant dedifferentiated liposarcomas [10]. Nomenclature and classification of lipomatous tumours has undergone major changes over time. Based on cytogenetic and molecular genetic studies, liposarcomas were classified by the World Health Organization Committee for classification of soft tissue tumours into five subtypes, atypical/well-differentiated liposarcoma, dedifferentiated liposarcoma, myxoid liposarcoma (including high grade round cell liposarcoma), pleomorphic liposarcoma and a rare mixed-type liposarcoma [8]. Some workers have proposed that the term ‘atypical lipomatous tumour’ should be used for tumours arising from extremities and chest wall, whereas ‘well differentiated liposarcoma’ should be used for describing tumours arising in the retroperitoneum and abdominal cavity [11,12,13].  Diagnosis of well differentiated liposarcomas of the extremities can be delayed due to relatively benign symptomatology and a low index of suspicion. Plantar fibromatosis and well differentiated liposarcoma can have a similar clinical presentation of a slow growing superficial well defined mass on the plantar aspect of foot. Here we present a patient of plantar fibromatosis mimicking a lipomatous tumour of the foot.

Case presentation
A 68-years-old male of Indian subcontinent was referred to our department with a ten year history of slow growing nodular masses on the non-weight bearing part of sole and along the lateral border of the right foot. The mass on the sole of the foot had become painful over the last one year. The masses were superficial, well defined, mildly tender and soft to firm in consistency (Fig. 1).  A diagnosis of plantar fibromatosis was made, keeping lipoma as a differential diagnosis. Plain radiographs showed no bony pathology. An unsuccessful trial of oral analgesics and customized insole was given. Prior to operative intervention for the mass on the plantar aspect of foot an excisional biopsy of the mass on the lateral border of the foot was performed. The biopsy revealed nodular non-encapsulated fibrofatty tissue on gross examination. Histopathological examination revealed nodular proliferation of adipocytes and myofibroblasts separated by collagenous bands. The nodules of fatty tissue showed a mixture of mature and immature fat cells with multivacuolation and nuclear indentation. Nuclear pleomorphism, hyperchromasia and mitosis were observed leading to a diagnosis of well differentiated liposarcoma. MRI revealed a 6.5cm x 6.6cm x 2cm well circumscribed, multilobulated lesion along the plantar aspect of the mid foot at the subcutaneous level that appeared to be indistinguishable from surrounding subcutaneous fat with internal linear strands. It was seen to insinuate between medial and lateral heads of plantar aponeurosis, however it did not show infiltration into the muscles of sole of the foot. Overlying skin of sole of foot appeared uninvolved. The lesion was hyperintense on T1w images, however suppresses completely on T2-STIR sequences. Few linear strands are noted tha are isointense in T1w images and showed enhancement in post contrast images (Fig. 2). Except for subtle focal edema in the base of the fifth metatarsal there was no bony involvement. Marginal resection of the remaining tumour was performed through an S-shaped incision on the non-weight bearing area of the sole. Tumour tissue was found to be lying between the dermis and the plantar aponeurosis. It was observed to be comprised of friable adipose tissue with a few intervening fibrotic septae. Tumor was non-encapsulated, however it could be easily separated from rest of the neighbouring structures. The adjacent aponeurosis and dermis appeared to be free of any gross tumour infiltration. The medial plantar neurovascular bundle also appeared free from any tumour infiltration. Histology revealed nodules of mature and immature adipose tissue separated by fibrovascular septae with areas of increased cellularity, pleomorphism, hyperchromasia and tumour giant cells (Fig. 3).  Mitotic figures were rare. Occasional cell with lipoblast like morphology was seen. Focal S-100 positivity was seen. Fatty tissue adherent to the skin also showed lesion cells in them. Due to proximity of tumour to the skin of the sole, thin skin flaps had to be created. Postoperatively marginal skin necrosis was observed and wound healing was delayed. Patient did not receive any postoperative chemotherapy or radiotherapy. At two years postoperatively, there has been no recurrence of the tumour and patient is able to ambulate without any discomfort. Patients consent was solicited before publishing the report

Discussion

Liposarcomas of the extremities are the second most commonly encountered soft tissue sarcoma after fibrous / fibrohistiocytic malignancies [14]. They occur almost exclusively in the age group between 40 to 60 years of age [14,15]. Liposarcomas are commonly encountered in the lower extremity, usually in the thigh, but rarely in the foot. Enzinger et al analyzed 1067 cases of liposarcoma, but none of them were in the foot [16]. There have been very few cases of liposarcomas of the foot reported in literature [17,18,19,20]. Preoperative diagnosis is infrequent. Hence, increasing the understanding of this tumour is important. WHO has categorized liposarcoma into five subtypes, out of which the well-differentiated variety is the most common, accounting for approximately 40% to 50% of all liposarcomas [21,14,22]. According to Evans et al a ‘well-differentiated liposarcoma’ and ‘atypical lipoma’ are identical in biological, behaviour, histological and karyotypic characteristics [23]. The term well differentiated liposarcoma is better used for lipomatous lesion in regions where wide resection is not possible (mediastinum and retroperitoneum), whereas the tumour is considered to be an atypical lipoma in other locations. Clinically, liposarcomas usually present as a painless soft tissue mass. Only around 10-15% liposarcomas present as a painful soft tissue mass [14]. These can be easily confused with fibromatosis which presents as slow growing single or multiple painful nodular thickenings [24]. A lipoma and a well-differentiated liposarcoma are also quite similar in clinical presentation. MR imaging is an essential tool for detection of liposarcoma as well as for studying its locoregional extension and relations (bone, soft-tissues and neurovascular involvement). MRI can help in differentiating between lipoma, liposarcoma and fibromatosis. Well-differentiated liposarcomas typically demonstrate a largely lipomatous mass, hyperintense on TW1 images, representing over 75% of the lesion in a nodular arrangement separated by thick non-lipomatous septae (>2mm but not exceeding 2cm). The non-lipomatous component shows variable enhancement on fat saturated T1w contrast enhanced images [25,26]. Lipomas also demonstrate abundant adipose tissue homogenously hyperintense on T1w images, similar to well-differentiated liposarcomas. However, lipomas have thin septae (<2mm) and contrast enhancement of lower signal intensity [21]. Fibromatosis on MRI shows nearly the same low-signal intensity as adjacent muscle on T1w and T2w images. Majority of fibromatosis show marked enhancement on gadolinium administration [27,28]. MRI must be performed prior to biopsy or any therapeutic management of a suspected liposarcoma. A well-differentiated liposarcoma appears grossly like a well-circumscribed multi-lobulated mass. Some sections of the tumour reveal mature adipose tissue in abundance that appears identical to a lipoma. However, a well-differentiated liposarcoma can be histologically identified by a typical scattering of lipoblasts with irregularly shaped hyperchromatic nuclei, along with thick fibrovascular septae [16]. Immunohistochemical analysis helps to distinguish a lipoma from a well-differentiated liposarcoma. MDM2 and CDK4 markers are expressed by a well-differentiated liposarcoma [29]. Fibromatosis can be identified based on its characteristic nodular cellular proliferation of plump, spindle shaped cells with intervening collagen with infrequent mitotic figures [30]. Well-differentiated liposarcomas are not known to have malignant potential but local recurrence risk is high [31]. For such tumours of the extremity, the local recurrence rate can be as high as 43% [32]. Such tumours are also reported to have undergone dedifferentiation into a more aggressive form with higher risk of local recurrence and metastasis [9].Prognosis and management of these tumours is related to their anatomical location. Most authors suggest that subcutaneously located tumours can be treated by wide resection, with minimal chances of local recurrence. Radiotherapy is not recommended unless there is gross residual tumour tissue. Chances of recurrence are much higher for tumours in deeper locations. Local recurrence can be treated by re-excision and radiotherapy [32,33,34]. Asymptomatic or mildly symptomatic lipomas of the extremity can be managed conservatively. Troublesome lipomas can be treated by simple excision. The management of fibromatosis can range from conservative management, intralesional steroid injections, collagenase injections, radiotherapy to surgical excision [35,36,37,38,39]. Due to such different lines of management of these pathologies, it is imperative to establish the correct diagnosis before proceeding to treatment. In this case, clinical presentation suggested a diagnosis of plantar fibromatosis, imaging studies suggested the possibility of a lipomatous tumour and histopathological evidence rasied the suspicion of a well differentiated liposarcoma. However, the final diagnosis of plantar fibromatosis was established after correlating the clinical features with a definitve histopathological evaluation following excision of the mass.


conclusions

Although plantar fibromatosis is a commonly encountered disease, it can be mimicked by rare pathologies like lipoma and liposarcoma. Hence, a high index of suspicion is required for their early diagnosis and proper surgical management. Management decisions should be taken after careful correlation between clinical, radiological and histopathological features.


References

1. Ledderhose H. Zur Pathologie der Aponeurose des Fusses und der Hand. Langenbecks Arch Klin Chir. 1897;55:694-712.
2. Cavolo DJ, Sherwood GF. Dupuytrens’s disease of the plantar fascia. J Foot Surg. 1982.21(1):12-15.
3. Weiss SW, Goldblum JR, Enzinger FM. Fibromatoses. In: Weiss SW, Goldblum JR editors. Enzinger and Weiss’ Soft Tissue Tumors. Philadelphia, Pa, USA: Mosby Elsevier;2008. p. 227–228.
4. Lee TH, Wapner KL, Hecht PJ. Plantar fibromatosis. J Bone Joint Surg Am. 1993;75(7):1080–1084.
5. Aviles E, Arlen M, Miller T. Plantar fibromatosis. Surgery. 1971;69(1):117–120.
6. Zgonis T, Jolly GP, Polyzois V, Kanuck DM, Stamatis ED. Plantar fibromatosis. Clin Podiatr Med Surg. 2005;22(1):11-18.
7. Mentzel T, Fletcher CD: Lipomatous tumours of soft tissues: An update. Virchow’s Arch. 1995; 427(4): 353-363.
8. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours. In: Fletcher CDM, Unni KK, Mertens F, editors. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon:IARC Press; 2002. p. 9-18.
9. Weiss SW, Rao VK. Welldifferentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. A follow-up study of 92 cases with analysis of the incidence of “Dedifferentiation”. Am J Surg Pathol 1992;16(11):1051-1058.
10. Dei Tos AP. Liposarcoma: New entities and evolving concepts. Ann Diagn Pathol. 2000;4(4):252-266.
11. Fletcher CD. Soft tissue tumours. In: Fletcher CD, editor. Diagnostic histopathology of tumours. 2nd edition. London:Harcourt Publishers Limited; 2000:1473–1540.
12. Kindblom LG, Angervall L, Fassina AS. Atypical lipoma. Acta Pathol Microbiol Immunol Scand [A]. 1982;90(1):27–36.
13. Evans HL, Soule EH, Winkelmann RK. Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma: a reappraisal of 30 cases formerly classified as well differentiated liposarcoma. Cancer. 1979;43(2):574–584.
14. Peterson JJ, Kransdorf MJ, Bancroft LW, O’Connor MI. Malignant fatty tumours: classification, clinical course, imaging appearance and treatment. Skeletal Radiol. 2003;32(9):493-503.
15. Munk PL, Lee MJ, Janzen DL, Connell DG, Logan PM, Poon PY, Bainbridge TC. Lipoma and liposarcoma: evaluation using CT and MR imaging. AJR Am J Roentgenol. 1997;169(2):589-594.
16. Enzinger FM, Weiss SW. Liposarcoma. In: Weiss SW, Goldblum JR, Folpe AL, editors. Soft Tissue Tumors. 3rd edition. St. Louis, Mosby, USA: Mosby Elsevier;1995:686-697.
17. Sugar S, Murphy BM. Liposarcoma of the foot; case report. J Mich State Med Soc. 1955;54(4):468–469.
18. Kelly PC, Shramowiat M. Liposarcoma of the foot: a case report. J Foot Surg. 1978;17(1):27–31.
19. Rajasekhar C, Paul AS, Bale RS. Spindle-cell liposarcoma: a rare variant of liposarcoma arising in the foot. Clin Oncol (R Coll Radiol). 2005;17(2):128–129.
20. Matsuo T, Sugita T, Shimose S, Kubo T, Yasunaga Y, Ochi M. Liposarcoma arising in the foot: a case report. Case Rep Med. 2009;2009:630203.
21. Kansdorf MJ, Bancroft LW, Peterson JJ, Murphey MD, Foster WC, Temple HT. Imaging of fatty tumours: distinction of lipoma and well-differentiated liposarcoma. Radiology. 2002;224(1):99-104.
22. Murphey MD, Arcara LK, Fanburg-Smith J. Imaging of musculosketal liposarcoma with radiologic-pathologic correlation. Radiographics 2005;25(5):13711395.
23. Evans H. Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol. 1979;3(6):507-523.
24. Chokshi FH, Jose J, Clifford PD. Plantar fibromatosis. Am J Orthop. 2009;38(9):475-476.
25. Matsumoto K, Takada M, Okabe H, Ishizawa M. Foci of signal intensities different from fat in well-differentiated liposarcoma and lipoma: correlation between MR and histological findings. J Clin Imaging. 2000;24(1):38-43.
26. Galant J, Martí-Bonmatí L, Sáez F, Soler R, Alcalá-Santaella R, Navarro M. The value of fat-suppressed T2 or STIR sequences in distinguishing lipoma from well-differentiated liposarcoma. Eur Radiol. 2003;13(2):337-343.
27. Walker EA, Petscavage JM, Brian PL, Logle CI, Montini KM, Murphey MD. Imaging features of superficial and deep fibromatoses in the adult population. Sarcoma [Internet]. 2012;2012. Epub 2012 Jun 28, Article ID 215810, 17 pages. Available from Hindawi at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395298/pdf/SRCM2012-215810.pdf
28. Morrison WB, Schweitzer ME, Wapner KL, Lackman RD. Plantar fibromatosis: a benign aggressive neoplasm with a characteristic appearance on MR images.Radiology. 1994;193(3):841-845.
29. Shimada S, Ishizawa T, Ishizawa K, Matsumura T, Hasegawa T, Hirose T. The value of MDM2 and CDK4 amplification levels using real time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. Hum Pathol. 2006;37(9):1123-1129.
30. Fetsch JF, Laskin WB, Miettinen M. Palmar-plantar fibromatosis in children and preadolescents: a clinicopathologic study of 56 cases with newly recognized demographics and extended follow-up information. Am J Surg Pathol. 2005;29(8):1095-1105.
31. Forus A, Larramendy ML, Meza-Zepeda LA, Bjerkehagen B, Godager LH, Dahlberg AB, Saeter G, Knuutila S, Myklebost O. Dedifferentiation of a welldifferentiated liposarcoma to a highly malignant metastatic osteosarcoma:amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases. Cancer Genet Cytogenet. 2001;125(2):100-111.
32. Kindblom LG, Angervall L, Svendsen P. Liposarcoma a clinicopathologic, radiographic and prognostic study. Acta Pathol Microbiol Scand Suppl. 1975;(253):1-71.
33. Kang J, Botros M, Goldberg S, Giraud C, Nielsen GP, Chen YL, Raskin K, Schwab J, Yoon SS, Hornicek FJ, Delaney TF. The Use of Radiation Therapy in the Management of Selected Patients with Atypical Lipomas. Sarcoma [Internet]. 2013;2013. Epub on 2013 Jan 15, Article ID 485483, 5 pages. Available from Hindawi at: http://www.hindawi.com/journals/sarcoma/2013/485483/
34. Sommerville SM, Patton JT, Luscombe JC, Mangham DC, Grimer RJ. Clinical outcomes of deep atypical lipomas (well-differentiated lipoma-like liposarcomas) of the extremities. ANZ Journal of Surgery. 2005;75(9):803–806.
35. Sammarco GJ, Mangone PG. Classification and treatment of plantar fibromatosis. Foot Ankle Int 2000;21(7):563-569.
36. Hammoudeh ZS. Collagenase Clostridium histolyticum injection for plantar fibromatosis (Ledderhose disease). Plast Reconstr Surg. 2014;134(3):497e-498e.
37. Grenfell S, Borg M. Radiotherapy in fascial fibromatosis: a case series, literature review and considerations for treatment of early-stage disease. J Med Imaging Radiat Oncol. 2014;58(5):641-647.
38. McNally EG, Shetty S. Plantar fascia: imaging diagnosis and guided treatment. Semin Musculoskelet Radiol. 2010;14(3):334-343.
39. Aluisio FV, Mair SD, Hall RL. Plantar fibromatosis: treatment of primary and recurrent lesions and factors associated with recurrence. Foot Ankle Int. 1996;17(11):672-678.


How to Cite this article: Bhatnagar N, Lingaiah P, Arora S, Dhal A. Plantar Fibromatosis Masquerading as Liposarcoma : a Case Report and Review of Literature. Journal of Bone and Soft Tissue Tumors May- Aug 2016;2(2):25-29.


                                          (Abstract    Full Text HTML)      (Download PDF)